https://go.evvnt.com/962696-0?pid=5248 The Westin Boston Seaport District
425 Summer Street
Boston, Massachusetts 02210
Lectures & Conferences
The 2nd Gene Therapy Medical Affairs Summit is dedicated to exploring the pivotal internal and external role Medical Affairs plays in delivering gene therapies to patients.
Whilst Gene Therapies are set to transform treatment paradigms, their complex nature and high price tag presents unique challenges. Learn how the global leaders of the gene therapy world are transforming the traditional role of medical affairs, from reactive to proactive strategic partners to launch gene therapy products more efficiently and effectively than ever before.
Join Orchard Therapeutics, PTC Therapeutics, Sanofi Genzyme and others as we start to define both the role and value of Medical Affairs from early development of gene therapies right the way to a launch environment.
Whether it is learning how to educate and upskill cross-functional teams or tailoring engagement strategies with external HCPs, regulators and patient advocates, join us to determine how best to create a cohesive and streamlined launch strategy specifically for gene therapy products.
We will delve into the unique challenge encountered when working with gene therapies, from adapting to the clinical realities of the rare disease space to handling long-term follow up and post-launch regulatory scrutiny, equipping you with the insights required to for a successful and patient-centric launch.
Group discounts and early booking rates are available. Please visit the website for full pricing information.
Conference + 3 Workshops: USD 4946.0,
Conference + 2 Workshops: USD 4297.0,
Conference + 1 Workshop: USD 3648.0,
Conference Only: USD 2999.0
Speakers: Kent Christopherson, Senior Director US Medical Affairs, Orchard Therapeutics, Ian Winburn, Global Medical Lead Haemophillia, Pfizer, Alexis Russell, Senior Director, US Gene Therapy, Therapeutic Area Lead PTC Therapeutics, Catherine Parham, Vice President, Head of Global Medical Affairs, Astellas Gene Therapies, Fatima Ahmad Vice President, Medical Affairs, Castle Creek Biosciences, Kathrin Kucharski, Senior Director Medical, Managed Care, Sarepta Therapeutics, Oscar Segurado, Chief Medical Officer, ASC Therapeutics, Ruth Haile-Meskale, Medical Science Liaison Lead, Gene Therapy, Hematology, Spark Therapeutics, Sandra Casiano, Senior Medical Director, Sanofi Genzyme